Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus GEMOX as first-line treatment for unresectable or metastatic biliary tract cancer
ChiCTR2100045251Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib, gemcitabine and oxaliplatin in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 6-month progression-free survival rate. Started May 2021; status: recruiting.
02
Drugs
surufatinibgemcitabineoxaliplatin
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100045251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045251.